GlassScriptPhysician profile
Kavitha Pinnamaneni
NPI 1669493573
$3,645.58
in general payments reported to CMS, 2019-2025
37 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2021: $503 · 2022: $252 · 2023: $546 · 2024: $784 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,976 · Education: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,976.35 |
| Education | $445.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $319.48 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $272.19 | 2019-2025 | Imfinzi, Imjudo |
| Glaxosmithkline, LLC. | $268.57 | 2021-2025 | Jemperli, Zejula, Blenrep |
| Pharmacyclics LLC, An Abbvie Company | $253.93 | 2021-2023 | Imbruvica, Epkinly |
| Pfizer INC. | $246.34 | 2021-2025 | |
| Astellas Pharma US INC | $227.75 | 2022-2025 | |
| Amgen INC. | $211.35 | 2019-2022 | |
| Seagen INC. | $199.54 | 2021-2023 | Padcev |
| E.R. Squibb & Sons, L.L.C. | $186.01 | 2019-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $162.99 | 2024-2025 | Enhertu |
| Abbvie INC. | $147.27 | 2024-2025 | |
| Intuitive Surgical, INC. | $139.84 | 2019 | |
| Celgene Corporation | $123.94 | 2022-2025 | Reblozyl, Pomalyst, Opdivo |
| Alexion Pharmaceuticals, INC. | $100.00 | 2019 | |
| Merck Sharp & Dohme LLC | $91.49 | 2025 | Keytruda, Welireg, Reblozyl |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kavitha Pinnamaneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.